132 related articles for article (PubMed ID: 36921897)
21. Analytical Considerations When Anchoring Discrete Choice Experiment Values Using Composite Time Trade-Off Data: The Case of EQ-5D-Y-3L.
Mott DJ; Devlin NJ; Kreimeier S; Norman R; Shah KK; Rivero-Arias O
Pharmacoeconomics; 2022 Dec; 40(Suppl 2):129-137. PubMed ID: 36396877
[TBL] [Abstract][Full Text] [Related]
22. Peruvian Valuation of the EQ-5D-5L: A Direct Comparison of Time Trade-Off and Discrete Choice Experiments.
Augustovski F; Belizán M; Gibbons L; Reyes N; Stolk E; Craig BM; Tejada RA
Value Health; 2020 Jul; 23(7):880-888. PubMed ID: 32762989
[TBL] [Abstract][Full Text] [Related]
23. Valuation Survey of EQ-5D-Y Based on the International Common Protocol: Development of a Value Set in Japan.
Shiroiwa T; Ikeda S; Noto S; Fukuda T; Stolk E
Med Decis Making; 2021 Jul; 41(5):597-606. PubMed ID: 33754886
[TBL] [Abstract][Full Text] [Related]
24. Randomised comparison of online interviews versus face-to-face interviews to value health states.
Peasgood T; Bourke M; Devlin N; Rowen D; Yang Y; Dalziel K
Soc Sci Med; 2023 Apr; 323():115818. PubMed ID: 36940582
[TBL] [Abstract][Full Text] [Related]
25. Testing "Pits" Time Trade-Off: Can Data Quality be Improved by Removing Death From Valuation of Health States?
Liao M; Yang Z; Rand K; Luo N
Value Health; 2024 May; ():. PubMed ID: 38795961
[TBL] [Abstract][Full Text] [Related]
26. Valuing the EQ Health and Wellbeing Short Using Time Trade-Off and a Discrete Choice Experiment: A Feasibility Study.
Mukuria C; Peasgood T; McDool E; Norman R; Rowen D; Brazier J
Value Health; 2023 Jul; 26(7):1073-1084. PubMed ID: 36805577
[TBL] [Abstract][Full Text] [Related]
27. Preference heterogeneity in health valuation: a latent class analysis of the Peru EQ-5D-5L values.
Karim S; Craig BM; Tejada RA; Augustovski F
Health Qual Life Outcomes; 2023 Jan; 21(1):1. PubMed ID: 36593473
[TBL] [Abstract][Full Text] [Related]
28. The EQ-5D-5L Valuation Study in Egypt.
Al Shabasy S; Abbassi M; Finch A; Roudijk B; Baines D; Farid S
Pharmacoeconomics; 2022 Apr; 40(4):433-447. PubMed ID: 34786590
[TBL] [Abstract][Full Text] [Related]
29. Exploring non-iterative time trade-off methods for valuation of EQ-5D-5L health states.
Yang Z; Rand K; Stolk E; Busschbach J; Luo N
Eur J Health Econ; 2023 Dec; ():. PubMed ID: 38104294
[TBL] [Abstract][Full Text] [Related]
30. Exploring EQ-5D-Y-3L Experience-Based VAS Values Derived Among Adolescents.
Åström M; Rolfson O; Burström K
Appl Health Econ Health Policy; 2022 May; 20(3):383-393. PubMed ID: 35083734
[TBL] [Abstract][Full Text] [Related]
31. Estimating an EQ-5D-3L Value Set for Romania Using Time Trade-Off.
Paveliu MS; Olariu E; Caplescu R; Oluboyede Y; Niculescu-Aron IG; Ernu S; Vale L
Int J Environ Res Public Health; 2021 Jul; 18(14):. PubMed ID: 34299864
[TBL] [Abstract][Full Text] [Related]
32. Parallel Valuation of the EQ-5D-3L and EQ-5D-5L by Time Trade-Off in Hungary.
Rencz F; Brodszky V; Gulácsi L; Golicki D; Ruzsa G; Pickard AS; Law EH; Péntek M
Value Health; 2020 Sep; 23(9):1235-1245. PubMed ID: 32940242
[TBL] [Abstract][Full Text] [Related]
33. A Time Trade-off-derived Value Set of the EQ-5D-5L for Canada.
Xie F; Pullenayegum E; Gaebel K; Bansback N; Bryan S; Ohinmaa A; Poissant L; Johnson JA;
Med Care; 2016 Jan; 54(1):98-105. PubMed ID: 26492214
[TBL] [Abstract][Full Text] [Related]
34. United States Valuation of EQ-5D-5L Health States Using an International Protocol.
Pickard AS; Law EH; Jiang R; Pullenayegum E; Shaw JW; Xie F; Oppe M; Boye KS; Chapman RH; Gong CL; Balch A; Busschbach JJV
Value Health; 2019 Aug; 22(8):931-941. PubMed ID: 31426935
[TBL] [Abstract][Full Text] [Related]
35. In search of a 'pan-European value set'; application for EQ-5D-3L.
Sajjad A; Versteegh MM; Santi I; Busschbach J; Simon J; Roijen LH
BMC Med Res Methodol; 2023 Jan; 23(1):13. PubMed ID: 36635625
[TBL] [Abstract][Full Text] [Related]
36. Valuation of EQ-5D-5L in the Kingdom of Saudi Arabia: A National Representative Study.
Al-Jedai A; Almudaiheem H; Al-Salamah T; Aldosari M; Almutairi AR; Almogbel Y; AlRuthia Y; Althemery AU; Alluhidan M; Roudijk B; Purba FD; Awad N; O'jeil R
Value Health; 2024 May; 27(5):552-561. PubMed ID: 38342365
[TBL] [Abstract][Full Text] [Related]
37. In a Child's Shoes: Composite Time Trade-Off Valuations for EQ-5D-Y-3L with Different Proxy Perspectives.
Lipman SA; Essers BAB; Finch AP; Sajjad A; Stalmeier PFM; Roudijk B
Pharmacoeconomics; 2022 Dec; 40(Suppl 2):181-192. PubMed ID: 36255560
[TBL] [Abstract][Full Text] [Related]
38. EQ-5D-5L Value Set for Slovenia.
Prevolnik Rupel V; Ogorevc M
Pharmacoeconomics; 2023 Nov; 41(11):1515-1524. PubMed ID: 37341959
[TBL] [Abstract][Full Text] [Related]
39. Comparison of online and face-to-face valuation of the EQ-5D-5L using composite time trade-off.
Jiang R; Shaw J; Mühlbacher A; Lee TA; Walton S; Kohlmann T; Norman R; Pickard AS
Qual Life Res; 2021 May; 30(5):1433-1444. PubMed ID: 33247810
[TBL] [Abstract][Full Text] [Related]
40. Estimating Utility Values for Health States of DFU Patients Using EQ-5D-5L and cTTO.
Arab-Zozani M; Safari H; Dori Z; Afshari S; Ameri H; Namiranian N; Hoseini E; Jafari A
Int J Low Extrem Wounds; 2022 Mar; 21(1):41-49. PubMed ID: 33939495
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
